NOTE

🌱 created from: bispecific_antibodies_for_relapse_and_refractory_multiple_myeloma

majestec-1

• Design: Phase 1-2 study, multi-center, open-label
• Number of patients: 165
• Patients characteristics: Relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure
• Agent: Teclistamab at a dose of 1.5 mg/kg body weight
• Treatment line: After at least three therapy lines, including triple-class exposure
• Trial Acronym or NCTId Number: NCT03145181 and NCT04557098

Parameter	Result
Response Rate	63.0%
Complete Response Rate	39.4%
MRD-negativity Rate	26.7%
Median Duration of Response	18.4 months (95% CI, 14.9 to not estimable)
Median Duration of PFS	11.3 months (95% CI, 8.8 to 17.1)

• Highlight of toxicity in majestec-1:
  • Common toxic effects included
    • cytokine release syndrome, neutropenia, anemia, thrombocytopenia, and infections.
    • Neurotoxic events occurred in a small percentage of patients.
• One line summary: Teclistamab showed promising efficacy in patients with triple-class–exposed relapsed or refractory multiple myeloma, with manageable toxicities.

Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2022;387(6):495-505. doi:10.1056/nejmoa2203478

• further Reading: COVID-19 and majestec-1